Dan Tomomasa

Dan Tomomasa

Auto-generated profile, based on publicly available information

Dan Tomomasa

Institute of Science Tokyo 1 Department of Pediatrics and Developmental Biology Tokyo

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2025 in Journal of Human Immunity
Verified
Journal Article
Open access
HKHirokazu Kanegane
Hirokazu Kanegane
KTKay Tanita
Kay Tanita
MNMadoka Nishimura
Madoka Nishimura
DTDan Tomomasa
Dan Tomomasa
KIKento Inoue
Kento Inoue
HOHans D. Ochs
Hans D. Ochs
Discovered >70 years ago by Ogden Bruton, X-linked agammaglobulinemia (XLA), characterized by recurrent bacterial infections, hypo/agammaglobulinemia, and peripheral blood B-cell deficiency, is among the best-established inborn errors of immunity (IEIs) and one of the most well-documented single types of IEIs, the incidence of which is estimated to be between 1:100,000 and 1:200,000. However, although the pathogenesis of XLA is well understood, several issues remain open for discussion. In this review, we describe several unresolved issues, including noncoding BTK variants, contiguous deletion syndrome, Helicobacter infection, noninfectious neurodegeneration, renal involvement, and malignancies. The primary treatment for XLA, immunoglobulin replacement therapy, administered either intravenously or subcutaneously, has remained unchanged since its discovery. Allogeneic hematopoietic cell transplantation has been successful in some XLA patients, but there are still few reports. However, it may be considered as a treatment option in the future. Given that XLA is one of the most common types of IEIs, resolving these issues is a priority.

5 December 2024 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KIKento Inoue
Kento Inoue
DTDan Tomomasa
Dan Tomomasa
YNYu Nakagama
Yu Nakagama
HTHiroaki Takeuchi
Hiroaki Takeuchi
YTYukie Tanaka
Yukie Tanaka
HKHirokazu Kanegane
Hirokazu Kanegane

23 October 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
HIHitoshi Irabu
Hitoshi Irabu
MNMadoka Nishimura
Madoka Nishimura
FSFumiaki Sakura
Fumiaki Sakura
TATakaki Asano
Takaki Asano
MHMaho Hatano
Maho Hatano
MSMasaki Shimizu
Masaki Shimizu
Clinical targeted sequencing identified low-VAF KRAS variants in two of 26 children with childhood-onset systemic lupus erythematosus (SLE). Both had severe inflammatory manifestations but lacked Noonan syndrome features, and neither developed persistent lymphoproliferation suggestive of RAS-associated autoimmune lymphoproliferative disease during follow-up. These findings suggest that KRAS mosaicism may contribute to the development or severity of childhood-onset SLE.

15 September 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
DTDan Tomomasa
Dan Tomomasa
TUTomoko Uehara
Tomoko Uehara
TTTomotada Takayama
Tomotada Takayama
MNMadoka Nishimura
Madoka Nishimura
RWRyosuke Wakatsuki
Ryosuke Wakatsuki
HKHirokazu Kanegane
Hirokazu Kanegane
A cluster of cases of IRAK4 deficiency has been identified in Okinawa Prefecture, Japan. All affected families carry the homozygous c.123_124insA variant, suggesting a founder effect and supporting the implementation of targeted newborn screening of IRAK4 deficiency in Okinawa.

12 March 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
DTDan Tomomasa
Dan Tomomasa
ANAkira Nishimura
Akira Nishimura
KYKenichi Yoshida
Kenichi Yoshida
YNYui Namikawa
Yui Namikawa
DKDoo Ri Kim
Doo Ri Kim
HKHirokazu Kanegane
Hirokazu Kanegane
X-linked lymphoproliferative syndrome type 1 (XLP1) is an inborn error of immunity caused by pathogenic variants in SH2D1A and is frequently complicated by Epstein-Barr virus (EBV)–associated lymphoproliferative disorders (LPDs). However, cases of LPD without EBV infection have been reported and remain poorly understood. We investigated tumorigenesis mechanisms through transcriptomic profiling and somatic variant analysis in tumor samples from six patients with XLP1. Pathogenic variants were identified in two: one developed two distinct LPDs harboring CARD11/GNA13 and MECOM variants, while the other carried IRF4, P2RY8, KRAS, and CCND3 variants. Transcriptome analysis of three tumors, compared with diffuse large B cell lymphoma from patients without an underlying immune defect, revealed a distinct expression profile. Gene Ontology analysis showed upregulation of adaptive immune response genes, including various IgH and TCR genes, suggesting polyclonal lymphocyte proliferation. Overall, LPD associated with XLP1 may originate from polyclonal lymphocyte expansion, either in the presence or absence of EBV infection, and subsequently progress to malignancy through somatic variants.

27 July 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
HKHirokazu Kanegane
Hirokazu Kanegane
DTDan Tomomasa
Dan Tomomasa
SOSatoshi Okada
Satoshi Okada
Activated phosphoinositide 3-kinase delta syndrome (APDS) is a form of common variable immunodeficiency (CVID) caused by gain-of-function variants in PIK3CD (APDS1) or loss-of-function variants in PIK3R1 (APDS2), resulting in hyperactivation of the PI3Kδ pathway. Clinically, it is characterized by recurrent respiratory infections, lymphadenopathy, splenomegaly, and progressive airway destruction, often leading to bronchiectasis. Enteropathy, cytopenia, and immune dysregulation have also been observed in several patients. Some patients develop malignant lymphomas, which can be fatal. Prophylactic antimicrobial therapy and regular immunoglobulin replacement therapy are administered in a manner similar to that used for CVID. However, since excessive activation of the class IA phosphoinositide 3-kinase signaling pathway is the primary pathophysiology of APDS, mammalian target of rapamycin inhibitors and selective p110δ inhibitors are expected to be licensed therapies. Early diagnosis based on diagnostic clues specific to APDS, followed by prompt treatment, is expected to improve patient prognosis.